Literature DB >> 3549162

A double-blind comparative trial of acyclovir and adenine arabinoside in combination with dilute betamethasone in the management of herpetic disciform keratitis.

L M Collum, D M Grant.   

Abstract

A double-blind comparative trial of acyclovir (ACV) and adenine arabinoside (ARA-A) in combination with dilute betamethasone was carried out in 30 patients with herpetic disciform keratitis. Of those receiving ACV and betamethasone, 86.7% healed in a mean time of 22.5 days, while 76.9% of those receiving the Ara-A combination healed in a mean time of 26.7 days. There was no statistical difference between the two treatment groups for efficacy parameters. However, the proportion of patients developing superficial punctate keratopathy (SPK) was significantly greater in the Ara-A treatment group.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549162     DOI: 10.3109/02713688709020094

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  6 in total

1.  A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis.

Authors:  S M Porter; A Patterson; P Kho
Journal:  Br J Ophthalmol       Date:  1990-05       Impact factor: 4.638

Review 2.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Corneal lymphangiogenesis in herpetic stromal keratitis.

Authors:  Paul J Park; Michael Chang; Nitin Garg; Jimmy Zhu; Jin-Hong Chang; Deepak Shukla
Journal:  Surv Ophthalmol       Date:  2014-06-10       Impact factor: 6.048

4.  Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group.

Authors:  K R Wilhelmus; C R Dawson; B A Barron; P Bacchetti; L Gee; D B Jones; H E Kaufman; J Sugar; R A Hyndiuk; P R Laibson; R D Stulting; P A Asbell
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

Review 5.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 6.  Adoption of Innovation in Herpes Simplex Virus Keratitis.

Authors:  James Chodosh; Lawson Ung
Journal:  Cornea       Date:  2020-11       Impact factor: 3.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.